Trending...
- California: Governor Newsom announces appointments 9.10.25 - 428
- John Thomas calls for unity and prayer after tragic loss - 389
- Ayurveda, Ayurvedic medical Science and Ayurvedic Therapies, Dr.Abhay Kumar Pati - 383
SAN DIEGO--(BUSINESS WIRE)--Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics, today announced the appointments of Olivia C. Ware and Katrin Rupalla, Ph.D., to its Board of Directors.
"We are thrilled to have both Olivia and Katrin join the Ambrx team at a such a pivotal time in the company's history," said Feng Tian, Ph.D., Chairman of the Board, President and CEO of Ambrx. "Olivia brings invaluable experience across all stages of the product development cycle, from pharmaceutical drug development and commercialization to healthcare management. Katrin has extensive experience in global regulatory strategy and drug candidate development. I look forward to benefiting from Olivia and Katrin's counsel in the months and years to come, as we advance our clinical development pipeline, including our lead asset ARX788."
"I am delighted to be appointed to Ambrx's Board and joining what I believe to be a very talented and highly capable team," said Ms. Ware. "I hope to leverage my clinical and commercial experience as we collectively seek to advance an innovative pipeline of drugs from Ambrx's technology platform."
Ms. Ware joins Ambrx with more than 20 years of pharmaceutical drug development, commercialization and healthcare management experience, with a history of successful commercial drug launches including Rituxan®, Herceptin®, Avastin® and Lucentis®. In addition to drug development, Ms. Ware also has experience in developing managed care, pricing and contract strategy, developing marketing programs for field-based sales teams, and establishing, growing and optimizing organizations for long-term success. Previously, Ms. Ware was the Senior Vice President, BTK Franchise Head at Principia Biopharma Inc., where she was responsible for developing portfolio strategy for the company's three BTKi molecules. Prior to that, she served as Senior Vice President, U.S. Market and Franchise Development at Proteus Digital Health, Inc., was Chief Commercial Officer at CytRx, Inc., and held various leadership roles at Genentech, Inc.
More on The Californer
Ms. Ware graduated from Davidson College and received her MBA from the University of North Carolina at Chapel Hill. She is now President of Davidson College Board of Visitors and member of the Davidson Board of Trustees.
"I'm excited to be joining Ambrx, especially given the recent clinical progress the company has made in both China and the United States," said Dr. Rupalla. "I look forward to assisting the company's regulatory affairs and drug development efforts in both countries, so that we can together progress Ambrx's innovative Engineered Precision Biologics to create more precise therapeutic treatments to address significant unmet needs."
Dr. Rupalla has more than 25 years' experience in the pharmaceutical industry at a global scale serving the United States, Europe and China. Currently, Dr. Rupalla serves as Senior Vice President of Regulatory Affairs, R&D Quality and Medical Information at Lundbeck. Prior to joining Lundbeck, she spent several years at Bristol Myers Squibb in various roles in drug development and regulatory affairs including as Head Development BMS in China, Vice President of European Union Regulatory Sciences, and Vice President of Oncology Global Regulatory Sciences. Dr. Rupalla has spent her career as an executive in global regulatory affairs at various other companies including Celgene, Roche, and Merck. Presently, she is a non-executive independent director at 4D Pharma PLC and iQure Pharma Inc.
More on The Californer
Dr. Rupalla received a Master of Science in Pharmacy and a Ph.D. in CNS pharmacology from Philipps University of Marburg, Germany. She also has an MBA from Jones International University, CO, USA.
About Ambrx
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs optimized for efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, the company has clinical collaborations with Bristol Myers Squibb, Astellas, BeiGene, Sino Biopharma, Elanco and NovoCodex, for drug candidates generated using Ambrx technology. For additional information, please visit www.ambrx.com.
"We are thrilled to have both Olivia and Katrin join the Ambrx team at a such a pivotal time in the company's history," said Feng Tian, Ph.D., Chairman of the Board, President and CEO of Ambrx. "Olivia brings invaluable experience across all stages of the product development cycle, from pharmaceutical drug development and commercialization to healthcare management. Katrin has extensive experience in global regulatory strategy and drug candidate development. I look forward to benefiting from Olivia and Katrin's counsel in the months and years to come, as we advance our clinical development pipeline, including our lead asset ARX788."
"I am delighted to be appointed to Ambrx's Board and joining what I believe to be a very talented and highly capable team," said Ms. Ware. "I hope to leverage my clinical and commercial experience as we collectively seek to advance an innovative pipeline of drugs from Ambrx's technology platform."
Ms. Ware joins Ambrx with more than 20 years of pharmaceutical drug development, commercialization and healthcare management experience, with a history of successful commercial drug launches including Rituxan®, Herceptin®, Avastin® and Lucentis®. In addition to drug development, Ms. Ware also has experience in developing managed care, pricing and contract strategy, developing marketing programs for field-based sales teams, and establishing, growing and optimizing organizations for long-term success. Previously, Ms. Ware was the Senior Vice President, BTK Franchise Head at Principia Biopharma Inc., where she was responsible for developing portfolio strategy for the company's three BTKi molecules. Prior to that, she served as Senior Vice President, U.S. Market and Franchise Development at Proteus Digital Health, Inc., was Chief Commercial Officer at CytRx, Inc., and held various leadership roles at Genentech, Inc.
More on The Californer
- Who Will Win the 2025 WNBA Finals? OddsTrader Shares Live Betting Odds and Projections
- Silva Construction Weighs In on the Most Popular Home Design Trends for 2026
- Geeks5g Creative Marketing: The Powerhouse Behind Business Growth
- Wise Business Plans Now Serves Entrepreneurs in Los Angeles with Tailored Business Plan Writing
- Proposition 1 continues delivering support for vulnerable homeless populations in California
Ms. Ware graduated from Davidson College and received her MBA from the University of North Carolina at Chapel Hill. She is now President of Davidson College Board of Visitors and member of the Davidson Board of Trustees.
"I'm excited to be joining Ambrx, especially given the recent clinical progress the company has made in both China and the United States," said Dr. Rupalla. "I look forward to assisting the company's regulatory affairs and drug development efforts in both countries, so that we can together progress Ambrx's innovative Engineered Precision Biologics to create more precise therapeutic treatments to address significant unmet needs."
Dr. Rupalla has more than 25 years' experience in the pharmaceutical industry at a global scale serving the United States, Europe and China. Currently, Dr. Rupalla serves as Senior Vice President of Regulatory Affairs, R&D Quality and Medical Information at Lundbeck. Prior to joining Lundbeck, she spent several years at Bristol Myers Squibb in various roles in drug development and regulatory affairs including as Head Development BMS in China, Vice President of European Union Regulatory Sciences, and Vice President of Oncology Global Regulatory Sciences. Dr. Rupalla has spent her career as an executive in global regulatory affairs at various other companies including Celgene, Roche, and Merck. Presently, she is a non-executive independent director at 4D Pharma PLC and iQure Pharma Inc.
More on The Californer
- Agemin Unveils Breakthrough AI Model for Biometric Age Estimation, Setting New Standards in Online Child Safety
- Turnout Secures $21M in Seed Funding to Fuel Mission to Simplify Government Bureaucracy
- Teamsters Local 2010, UC Labor Unions File Historic Lawsuit Against Trump Administration
- Strategic Partnerships with Defiant Space Corp and Emtel Energy USA Powerfully Enhance Solar Tech Leader with NASA Agreements: Ascent Solar $ASTI
- 120% Revenue Surge with Four Straight Profitable Quarters Signal a Breakout in the Multi-Billion Dollar Homebuilding Market: Innovative Designs $IVDN
Dr. Rupalla received a Master of Science in Pharmacy and a Ph.D. in CNS pharmacology from Philipps University of Marburg, Germany. She also has an MBA from Jones International University, CO, USA.
About Ambrx
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to create Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs optimized for efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, the company has clinical collaborations with Bristol Myers Squibb, Astellas, BeiGene, Sino Biopharma, Elanco and NovoCodex, for drug candidates generated using Ambrx technology. For additional information, please visit www.ambrx.com.
Filed Under: Business
0 Comments
Latest on The Californer
- Sharks and Seaside Resilience in Great White Summer on Documentary Showcase
- Finding LVN Jobs in Los Angeles: A Premier Local Agency in LA County Offers Personalized Help
- Work 365 Launches PV 3.0: The Keystone Power App for Microsoft CSPs
- Affinity Nightlife's Post Awards After Party Celebrated with the Industry's Biggest Stars
- Local consultant shows small businesses how to turn red tape into real money
- Stringify AI Launches Complaint Classifier to Automate Enterprise Support Triage
- Hazel-E Hosts Pop-Up Gifting Suite on Melrose
- iPOP Administration & Talent Fund Clean Water Project in Africa, Through the Thirst Project
- California: Governor Newsom announces appointments 9.16.25
- Hollywood Veterans and Rising Stars Join Forces on "HOA" A Vertical Sitcom Designed for Social Media
- LVN Jobs in LA Establishes Local Presence Offers In-Person Staffing Solutions for LA LVN Job Seekers
- Meet a Scientologist Tunes Up with Auto Expert Jimmy Alauria
- City of Long Beach Launches Second Cohort of Urban Planning and Design Internship Program
- California: Governor Newsom launches new statewide service effort to support the well-being of young men
- California: Governor, First Partner statement on the passing of Robert Redford
- 'The Lonely Diners Club' Goes Into Pre-Production
- Tour Napa Like a Local: Vines of Napa Valley Wine Passport AKA Vine Pass Unlocks Hidden Gems
- Changzhou Huifeng Vehicle Parts Factory Continues Participation 2025 AAPEX Show at Las Vegas
- Dental Surgical Center Accepts Sedation Patients with Medicaid for MD, WV, PA and DC
- Attn: Business: Looking for ways to Increase your Sales and Profit? Start using this Marketing Math